China leads the world in AI research publications related to the global medical device field over the past five years, according to a latest industrial white paper.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Roche (SIX: RO, ROG; OTCQX: RHHBY), in collaboration with KlinRisk, Inc., has received the CE-mark for the first AI-based risk stratification tool to assess progressive decline in kidney function. This milestone allows Roche to introduce the Chronic Kidney Disease (CKD) algorithm panel on its navify® Algorithm Suite to support care across all stages of the CKD care pathway. The panel includes the new Kidney Klinrisk Algorithm - for early risk assessment of adults diagnosed with CKD as well as adults with diabetes or hypertension at elevated risk for kidney function decline - alongside the established CE-marked Kidney KFRE Algorithm (KFRE) for managing later disease stages of CKD.

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

SmartLabs and Sonrai Analytics (Sonrai) today announced a global strategic partnership designed to bring Sonrai's next-generation AI capabilities directly into SmartLabs' network of advanced research centers. Under this agreement, SmartLabs will begin offering Sonrai's AI advanced analytics platform, Sonrai Discovery, to its member companies. Both companies will also develop new laboratory informatics and bespoke AI applications that will integrate experimental and infrastructure data to predict scientific outcomes and accelerate discovery, exclusively to the SmartLabs' network.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio.

Ant Group has announced a strategic partnership with Peking University Third Hospital in Beijing to establish a joint AI healthcare innovation laboratory.

PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation’s top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI’s digital pathology platform, AISight® Dx, across Moffitt’s pathology programs to transform cancer detection and innovation.